Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an ‘Overweight’ rating on the stock with a $145 price target.

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...

SLNO. 3.14%. Capnia Inc stock, with a market capitalization of $4.1 billion, has reached a new 52-week high, hitting 82.42 USD. According to InvestingPro analysis, the stock is currently trading ...

Find the latest on short interest, settlement dates, average share volume, and days to cover for Soleno Therapeutics, Inc. Common Stock (SLNO) at Nasdaq.com.